Business
Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology
Insilico Medicine ("Insilico"), a world-leading artificial intelligence (AI)-driven drug discovery company, today announced a multi-year research and development (R&D) collaboration with Servier, an independent international pharmaceutical company governed by a foundation. This strategic alliance is focused on identifying and developing novel therapeutics for challenging targets in the oncology space by leveraging Insilico's proprietary AI platform, Pharma.AI.
About this update from Insilico Medicine Cayman Topco
[{"type":"list","items":[{"val":[{"type":"text","content":"Insilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, focused on discovering and developing innovative oncology therapies, by combining Insilico's AI-driven drug discovery platforms with Servier's global expertise in cancer drug development.","length":327,"tagName":"p"}]},{"val":[{"type":"text","content":"Under the terms of the agreement, Insilico will be eligible to receive up to US$32 million in upfront and near-term R&D payments and will leverage its proprietary AI-powered technologies to identify and advance potential drug candidates that meet predefined scientific and development criteria.","length":303,"tagName":"p"}]},{"val":[{"type":"text","content":"Servier will participate in sharing research and development costs, and, upon the successful identification of promising candidates, will lead subsequent clinical validation, regulatory interactions, and worldwide commercialization of the resulting oncology drug candidates.","length":299,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":929,"olType":false},{"type":"text","content":"CAMBRIDGE, Mass., Jan. 4, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"), a world-leading artificial intelligence (AI)-driven drug discovery company, today announced a multi-year research and development (R&D) collaboration with Servier, an independent international pharmaceutical company governed by a foundation. This strategic alliance is focused on identifying and developing novel therapeutics for challenging targets in the oncology space by leveraging Insilico's proprietary AI platform, Pharma.AI.","length":574,"tagName":"p"},{"type":"text","content":"Under the agreement, Insilico will be eligible to receive up to US$32 million in upfront and near-term R&D payments and will lead the AI-driven discovery and development of potential drug candidates that meet predefined criteria, while Servier will share the R&D expenses and lead clinical validation and commercialization processes.","length":361,"tagName":"p"},{"type":"text","content":""This collaboration underscores Servier's commitment to applying cutting-edge technologies to addr...